Emerging strategies and agents to lower cardiovascular risk by increasing high density lipoprotein cholesterol levels

Current Medicinal Chemistry
Scott Greenfeder

Abstract

For decades, the focus of therapy to mitigate cardiovascular risk has been to lower low density lipoprotein cholesterol (LDL-C), so called "bad cholesterol". Widespread use of statins has resulted in a large body of clinical experience, which indicates that lower LDL-C levels do indeed correlate with decreased risk of cardiovascular and coronary artery diseases (CVD and CAD). Given these findings, recommended targets for LDL-C levels are continually being revised lower. Interestingly, however, even at low LDL-C levels there remains a substantial residual risk of CVD and CAD, particularly in patients with additional contributing factors. Recent post-hoc analyses of several large lipid modulation trials specifically assessing high density lipoprotein cholesterol (HDL-C) have revealed that increased HDL-C levels confer additional benefit against risk of CVD and CAD, even when LDL-C levels are already low. Human clinical outcomes trials that specifically target increasing HDL-C have not yet been conducted. However, the strong epidemiological inverse correlation between HDL-C and CVD risk remains. Discovery efforts aimed at increasing circulating levels of HDL-C have increased dramatically in recent years. This review will cover rec...Continue Reading

Citations

Feb 8, 2011·Journal of Immigrant and Minority Health·Maria I Van RompayKatherine L Tucker
Nov 17, 2011·International Journal of Occupational Medicine and Environmental Health·Mohammad Reza NaghiiMehdi Hedayati
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Serhan KüpeliMünevver Büyükpamukçu
Feb 16, 2020·British Journal of Pharmacology·Ulises MezaAldo A Rodríguez-Menchaca

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Current Treatment Options in Cardiovascular Medicine
Nadia Khoury, Anne Carol Goldberg
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
I J JonkersA van der Laarse
Zeitschrift für Kardiologie
I Gouni-Berthold, W Krone
Nederlands tijdschrift voor geneeskunde
S D Niemeijer-KantersD W Erkelens
© 2021 Meta ULC. All rights reserved